Biomedical Research Foundation Academy Of AthensAcademy Of Athens
Scientific Personnel

Evangelos Evangelos Andreakos, PhD
Investigator - Associate Professor Level

Telephone : +30 210 6597 338
Fax : +30 210 6597 348
e-mail : vandreakos@bioacademy.gr


Center :

Clinical, Experimental Surgery & Translational Research

Lab Site :

Andreakos Lab


Brief Bio

Dr Evangelos Andreakos is Principal Investigator (Assoc. Professor Level) at the Centre for Clinical, Experimental Surgery and Translational Research of the Biomedical Research Foundation of the Academy of Athens (BRFAA). He received his PhD in Immunology from Imperial College London at the Kennedy Institute of Rheumatology in the UK under the supervision of Prof. Sir Marc Feldmann that pioneered the development of biological therapies for chronic inflammatory diseases. He then conducted postdoctoral research at the team of Prof. Brian Foxwell at Imperial College London, a leading expert in immune cell signaling.

His current research seeks to seeks to understand how innate immunity, the body's natural defense against exogenous and endogenous insults, controls host protective versus host damaging inflammation. It particularly focuses on the role of innate immune disturbances in the development of respiratory diseases such as asthma and acute respiratory distress syndrome. It also investigates the involvement of innate immune pathways in the pathophysiology of atherosclerosis. Major recent contributions of his team include the discovery of lambda interferons as a non-inflammatory class of interferons that mediate front-line antiviral protection without causing damage (Galani et al. Immunity 2017), the characterization of plasmacytoid DCs as central mediators of asthma exacerbations (Chairakaki et al. J Allergy Clin Immunol 2017) and the uncovering of novel anti-inflammatory and proresolving functions of Toll-like receptor 7 (TLR7) in allergic asthma (Koltsida et al. EMBO Mol Med 2013; Xirakia et al. Am J Respir Crit Care Med 2010) and atherosclerosis (Salagianni et al. Circulation 2012).  The long-term goal is translational, aiming at identifying key regulatory knots and developing novel approaches for therapeutic intervention. The laboratory of E. Andreakos at BRFAA is receiving research funding from the Europe Commission, national research bodies, charities and the pharmaceutical industry. 

Dr Andreakos has published >60 papers and reviews in high impact international journals including Immunity, PNAS, Circulation, Blood, Science Transl Med, Am J Respir Crit Care Med, J Allergy Clin Immunol and EMBO Mol Med, and has given numerous lectures and presentations as an invited speaker in international conferences, leading Universities and pharmaceutical companies. He is also inventor of three patents. He acts as an Expert Advisor/Panel member in several scientific committees including the European Commission, professional bodies and Medical Societies, and has extensive experience in collaborations and consultancy with the pharmaceutical industry and start-up biotechnology companies

Selected Publications

Chairakaki AD, Saridaki MI, Pyrillou K, Mouratis MA, Koltsida O, Walton RP, Bartlett NW, Stavropoulos A, Boon L, Rovina N, Papadopoulos NG, Johnston SL and Andreakos E. Plasmacytoid dendritic cells drive acute exacerbations of asthma. J Allergy Clin Immunol 2017 In Press

Galani IE, Triantafyllia V, Eleminiadou EE, Koltsida O, Stavropoulos A, Manioudaki M, Thanos D, Doyle SE, Kotenko SV, Thanopoulou K, Andreakos E. Interferon-λ Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness. Immunity 2017; 46(5):875-890

Galani IE and Andreakos E. Neutrophils in viral infections: Current concepts and caveats. J Leuk Biol 2015; 98(4):557-64

Koltsida O, Karamnov S, Pyrillou K, Vickery T, Tamvakopoulos C, Sideras P, Serhan CN and Andreakos Ε*. Toll-like receptor 7 stimulates production of specialized pro-resolving lipid mediators and promotes resolution of experimental asthma. EMBO Mol Med 2013; 5(5):762-75

Salagianni M, Galani IE, Lundberg AM, Davos CH, Varela A, Gavriil A, Lyytikäinen LP, Lehtimäki T, Sigala F, Folkersen L, Gorgoulis V, Lenglet S, Montecucco F, Mach F, Hedin U, Hansson GK, Monaco C, Andreakos E. Toll-like receptor 7 protects from atherosclerosis by constraining ‘inflammatory’ macrophage activation. Circulation 2012;126(8):952-62

Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Übel C, Kotenko SV, Sideras P, Lehr HA, Tepe M, Klucher KM, Doyle SE, Neurath MF, Finotto S and Andreakos E*. IL-28A(IFN-λ2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med 2011; 3(6):348-61

Xirakia C, Koltsida O, Thanassopoulou A, Aidinis V, Sideras P, Andreakos E. TLR7-triggered antiviral response in the lung mediates acute and long-lasting suppression of experimental asthma. Am J Respir Crit Care Med 2010;181(11):1207-16.

Andreakos E, Williams RΟ, Wales J, Foxwell BΜ and Feldmann M. Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. Proc Natl Acad Sci USA 2006;103(39):14459-64

Monaco C, Andreakos E, Kiriakidis S, Mauri C, Bicknell C, Foxwell B, Cheshire N, Paleolog E, Feldmann M. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA 2004;101(15):5634-9

Andreakos E, Sacre S, Smith C, Lundberg A, Kiriakidis S, Stonehouse T, Monaco C, Feldmann M and Foxwell BM. Distinct pathways of LPS-induced NF-kappa B activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. Blood 2004;103(6):2229-37

PubMed:

PubMed Link